LEPR and prostate carcinoma: Indeed, meta-analysis of 16 published studies of 6569 cases and 8405 controls for the leptin receptor G2548A mutation showed that it is statistically significantly associated with an increased risk of prostate cancer (OR=1.26, 95% CI=1.05-1.51) [17].